Development and distribution of NAT test kits and automation solutions for blood donor screening

GFE Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH

Frankfurt am Main (Altenhöferallee 3, FiZ) · Frankfurt (In der Schildwacht)New on Amplifa

2005Founded

11–50Employees

2Locations in Frankfurt am Main

About GFE

GFE was founded in 2005 by three DRK blood donation services and is one of the first companies to use Nucleic Acid Amplification Technology (NAT) for the early detection of HCV, HBV, and HIV in blood donor screening. The company develops and distributes CE-IVD-marked, ready-to-use NAT test kits for all transfusion-relevant viruses. With the PoET® instrument, a fully automated system with on-board pooling is available, optimizing the laboratory workflow. The assays utilize multi-dye and multi-target techniques and are characterized by high sensitivity, specificity, and robustness against target mutations. The product portfolio includes the PoET® Multiscreen Assay (HCV, HBV, HIV-1/2), the PoET® Universal Positive Control, and the PoET® CMV Assay for the highly precise detection of Cytomegalovirus. The headquarters are located at the Frankfurt Biotechnology Innovation Center (FiZ) in Frankfurt am Main; distribution in Germany is handled by Seegene Germany GmbH.

Site: Frankfurt am Main
Processes: CE-IVD-marked NAT test kits (ready-to-use), PoET® Instrument – fully automated system with on-board pooling, PoET® Multiscreen Assay (HCV, HBV, HIV-1/2), PoET® Universal Positive Control, PoET® CMV Assay
Materials: Nucleic Acid Amplification Technology (NAT), Multi-Dye and Multi-Target Assays
Certificates: CE-IVD
Founded: 2005
Employees: 11-50
Industries: Blood Donation Services / Transfusion Medicine, In-vitro Diagnostics, Molecular Diagnostics

01
Research and Development
02
Assay Development (Multi-Dye, Multi-Target)
03
Manufacturing of CE-IVD Test Kits
04
Distribution via Seegene Germany GmbH

Technologies and Procedures

NAT

Nucleic Acid Amplification Technology (NAT)

Core procedure for molecular detection of HCV, HBV, HIV, and CMV in blood donor screening.

Multi-Target

Multi-Dye and Multi-Target Assays

Increases sensitivity, specificity, and robustness against target mutations.

Locations

Frankfurt am Main

Headquarters at the Frankfurt Biotechnology Innovation Center (FiZ)

Materials: NAT Assays

PoET® Instrument (fully automated, on-board Pooling)

Frankfurt (In der Schildwacht)

Location

Products

**PoET® Instrument**Fully automated NAT screening system · Blood Donation Services

Industries

Blood Donation Services / Transfusion MedicineIn-vitro DiagnosticsMolecular Diagnostics

Additional services

CE-IVD-marked NAT test kits (ready-to-use)PoET® Instrument – fully automated system with on-board poolingPoET® Multiscreen Assay (HCV, HBV, HIV-1/2)PoET® Universal Positive ControlPoET® CMV Assay

Reference customers

Blood Donation Services of the German Red Cross (Founding Partner)

Quality

GFE supports quality assurance through standardized proficiency testing, which validates the performance of the assays across laboratories, operators, and test runs.

Evidence	Frankfurt am Main
CE-IVD

History

2005
Founded by three DRK blood donation services; among the first companies to use NAT technology for the detection of HCV, HBV, and HIV in blood donor screening